Sartorius Stedim Biotech SA
PAR:DIM
Intrinsic Value
Sartorius Stedim Biotech SA provides equipment and services for the development, quality assurance, and production processes of the biopharmaceutical industry. [ Read More ]
The intrinsic value of one
DIM
stock under the Base Case scenario is
252.11
EUR.
Compared to the current market price of 226 EUR,
Sartorius Stedim Biotech SA
is
Undervalued by 10%.
Whether you're assessing long-term stability or short-term opportunities, Historical Valuation serves as a vital tool to enhance your investment approach, enabling you to make more informed investment decisions.
Sign up
to access Sartorius Stedim Biotech SA's intrinsic value history.
No restrictions, no limits.
All stocks, all tools.
Look for stocks that have been historically overvalued but are now trading below their intrinsic value.
Avoid stocks that are always undervalued and never reach their intrinsic value.
Find stocks that have historically corrected quickly from being undervalued to reaching their intrinsic value.
There are two methods to calculate the Intrinsic Value of a stock: DCF Valuation and Relative Valuation. We take the average of these two methods to estimate the intrinsic value as accurately as possible. You can see the Intrinsic Value of a stock at the top of this page.
DCF Value
Discounted Cash Flow
Fundamental Analysis
Balance Sheet Decomposition
Sartorius Stedim Biotech SA
| Current Assets | 1.6B |
| Cash & Short-Term Investments | 134m |
| Receivables | 350m |
| Other Current Assets | 1.1B |
| Non-Current Assets | 3.6B |
| Long-Term Investments | 24.4m |
| PP&E | 1.5B |
| Intangibles | 2B |
| Other Non-Current Assets | 60.2m |
| Current Liabilities | 922m |
| Accounts Payable | 440m |
| Accrued Liabilities | 81.1m |
| Other Current Liabilities | 401m |
| Non-Current Liabilities | 1.7B |
| Long-Term Debt | 1.3B |
| Other Non-Current Liabilities | 364m |
DIM Profitability Score
Profitability Due Diligence
Sartorius Stedim Biotech SA's profitability score is 70/100. The higher the profitability score, the more profitable the company is.
Score
Sartorius Stedim Biotech SA's profitability score is 70/100. The higher the profitability score, the more profitable the company is.
DIM Solvency Score
Solvency Due Diligence
Sartorius Stedim Biotech SA's solvency score is 74/100. The higher the solvency score, the more solvent the company is.
Score
Sartorius Stedim Biotech SA's solvency score is 74/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
DIM Price Targets Summary
Sartorius Stedim Biotech SA
According to Wall Street analysts, the average 1-year price target for
DIM
is 310.49 EUR
with a low forecast of 272.7 EUR and a high forecast of 409.5 EUR.
Shareholder Return
DIM Price
Sartorius Stedim Biotech SA
| Average Annual Return | 52.09% |
| Standard Deviation of Annual Returns | 56.37% |
| Max Drawdown | -61% |
| Market Capitalization | 20.8B EUR |
| Shares Outstanding | 92 167 279 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Sartorius Stedim Biotech SA
Country
Industry
Market Cap
Dividend Yield
Description
Sartorius Stedim Biotech SA provides equipment and services for the development, quality assurance, and production processes of the biopharmaceutical industry. The company is headquartered in Aubagne, Paca and currently employs 10,409 full-time employees. The firm covers the segments of biotechnology and mechatronics. Sartorius provides services which help customers to implement complex and quality-critical processes in biopharmaceutical production and laboratory environments in a time- and cost-efficient way. The Company’s customers are from the biotech, pharma and food industries, as well as from public research institutes and laboratories. Sartorius operates its own production facilities in Europe, Asia and America, and also has sales offices and local representatives in more than 110 countries. The firm operates through its subsidiaries, including Sartorius Stedim Austria GmbH, Sartorius Stedim Plastics GmbH, BioOutsource Ltd and Wave Biotech AG, among others.
Contact
IPO
Employees
Officers
The intrinsic value of one
DIM
stock under the Base Case scenario is
252.11
EUR.
Compared to the current market price of 226 EUR,
Sartorius Stedim Biotech SA
is
Undervalued by 10%.
Sensibly Priced Quality
Significantly Undervalued
Magic Formula
High Growth
